V12 SENTINEL ENGINE · AI MARKET ANALYSIS
S-ClassAbout S-Class
C
CSTLAI Stock Diagnostic Report

Castle Biosciences surges 67% after InvestingPro Fair Value call

Castle Biosciences' stock price surged 67% due to the impact of InvestingPro's fair value assessment.

View Source Article ↗
AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$34.20000076293945Reference entry price at analysis time
01
MARKET SNAPSHOT

Key Indicators at a Glance

RSI (14)65.04Neutral
Moving Average AlignmentNot AlignedTrend needs confirmation
Volume vs 20-Day Average1.11×Normal
7-Day Change8.8%Short-term rise/flat
Major Support23.73
Near-Term Resistance34.70
02
FUNDAMENTALS

Financial & Fundamental Analysis

In response to InvestingPro's fair value assessment report, there has been a significant upward trend, indicating a phase where short-term market participants are entering the market.
03
TECHNICAL VIEW

Technical Position & Response Criteria

The current price is near the 20-day high resistance level ($34.70), so we need to monitor for a potential breakout and any short-term profit-taking sell orders.
Support23.73
Resistance34.70
04
CATALYST & STRATEGY

Catalyst Analysis & Forward Strategy

The InvestingPro Fair Value assessment for Castle Biosciences has acted as a catalyst, resulting in a 67% surge in its stock price.
05
PROOF OF WORK

Analysis Point vs. Subsequent Price Action

INITIAL · At Analysis (2026-08-23)
FINAL · Current/Verified

Renders the actual stored OHLC data directly in your browser.

+
ANALYSIS HISTORY

CSTL Analysis History (Last 30 Days)

Diagnosed AtTickerAI ScoreTier
2026-08-23 11:45:23CSTL85S-ClassView Report →
2026-07-31 07:56:50CSTL85S-ClassView Report →
2026-07-01 21:44:15CSTL30RowView Report →
View Full History for CSTL (Blueprint) →